Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals
PLOS ONE · 17.04.2024 · 19 (4) · e0293703
DOI: 10.1371/journal.pone.0293703 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 17.04.2024. Verfasst von Amita Datta-Mannan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Exploratory Medicine and Pharmacology, Lilly Corporate Center, Indianapolis, IN, United States of America. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Immunoconjugates. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Many oncology antibody-drug conjugates (ADCs) have failed to demonstrate efficacy in clinic because of dose-limiting toxicity caused by uptake into healthy tissues. We developed an approach that harnesses ADC affinity to broaden the therapeutic index (TI) using two anti-mesenchymal-epithelial transition factor (MET) monoclonal antibodies (mAbs) with high affinity (HAV) or low affinity (LAV) conjugated to monomethyl auristatin E (MMAE). The estimated TI for LAV-ADC was at least 3 times greater than the HAV-ADC. The LAV- and HAV-ADCs showed similar levels of anti-tumor activity in the xenograft model, while the 111 In-DTPA studies showed similar amounts of the ADCs in HT29 tumors. Although the LAV-ADC has ~2-fold slower blood clearance than the HAV-ADC, higher liver toxicity was observed with HAV-ADC. While the SPECT/CT 111 In- and 124 I- DTPA findings showed HAV-ADC has higher accumulation and rapid clearance in normal tissues, intravital microscopy (IVM) studies confirmed HAV mAb accumulates within hepatic sinusoidal endothelial cells while the LAV mAb does not. These results demonstrated that lowering the MET binding affinity provides a larger TI for MET-ADC. Decreasing the affinity of the ADC reduces the target mediated drug disposition (TMDD) to MET expressed in normal tissues while maintaining uptake/delivery to the tumor. This approach can be applied to multiple ADCs to improve the clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Exploratory Medicine and Pharmacology, Lilly Corporate Center, Indianapolis, IN, United States of America.
- Bioproduct Research & Development, Lilly Technology Center North, Indianapolis, IN, United States of America.
- Drug Disposition/Commercialization, Lilly Corporate Center, Indianapolis, IN, United States of America.
- Biotechnology Discovery Research, Lilly Technology Center North, Indianapolis, IN, United States of America.
- Department of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, United States of America.
ORCID-Profile: Amita Datta-Mannan
Zitieren
APA
Datta-Mannan, A., Choi, H., Jin, Z., Liu, L., Lu, J., Stokell, D. J., Murphy, A. T., Dunn, K. W., Martinez, M. M., & Feng, Y. (2024). Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals. PLOS ONE, 19(4), e0293703. https://doi.org/10.1371/journal.pone.0293703
Vancouver
Datta-Mannan A, Choi H, Jin Z, Liu L, Lu J, Stokell DJ, et al. Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals. PLOS ONE. 2024;19(4):e0293703. doi:10.1371/journal.pone.0293703
BibTeX
@article{DattaMannan2024,
author = {Datta-Mannan, Amita and Choi, Hiuwan and Jin, Zhaoyan and Liu, Ling and Lu, Jirong and Stokell, David J and Murphy, Anthony T and Dunn, Kenneth W and Martinez, Michelle M and Feng, Yiqing},
title = {Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {4},
pages = {e0293703},
doi = {10.1371/journal.pone.0293703}
}
EUVIMED